Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling

BMC Clinical Pathology

Volumn 14, Issue 1, 2014, Pages

  Sandanayake, Neomal S ^a,c   Camuzeaux, Stephane ^a   Sinclair, John ^a   Blyuss, Oleg ^a   Andreola, Fausto ^a   Chapman, Michael H ^a,b   Webster, George J ^a,b   Smith, Ross C ^c   Timms, John F ^a   Pereira, Stephen P ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; MALDI TOF MS; PSC; Serum peptide biomarker

Indexed keywords

EID: 84893168358     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-14-7     Document Type: Article

References (43)

1. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Rizvi S, Gores GJ, Gastroenterology 2013 145 6 1215 29 10.1053/j.gastro.2013.10.013 24140396
2. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC, J Hepatol 2002 37 6 806 813 10.1016/S0168-8278(02)00297-0 12445422 (Pubitemid 35404220)
3. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Patel T, Hepatology 2001 33 6 1353 1357 10.1053/jhep.2001.25087 11391522 (Pubitemid 32496970)
4. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH, Ann Surg 2001 234 4 507 517 discussion 517-509 10.1097/00000658-200110000-00010 11573044 (Pubitemid 32946713)
5. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, Kudo T, Todo S, World J Surg 2005 29 6 728 733 10.1007/s00268-005-7761-9 15880276 (Pubitemid 41187533)
6. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, Miyazaki M, Br J Surg 2002 89 12 1525 1531 10.1046/j.1365-2168.2002.02268.x 12445060 (Pubitemid 35404319)
7. Novel diagnostic and prognostic biomarkers in biliary tract cancer. Skipworth JRA, Timms JF, Pereira SP, Expert Opin Med Diagn 2013 7 5 487 99 10.1517/17530059.2013.826646 23971898
8. Role of tumour markers, cytogenetics. Lamerz R, Ann Oncol 1999 10 Suppl 4 145 149 10.1093/annonc/10.suppl-4.S145 10436809
9. The clinical utility of the CA 19-9 tumor-associated antigen. Steinberg W, Am J Gastroenterol 1990 85 4 350 355 2183589 (Pubitemid 20140602)
10. Identification of gastric cancer patients by serum protein profiling. Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, Malfertheiner P, Rocken C, J Proteome Res 2004 3 6 1261 1266 10.1021/pr049865s 15595736 (Pubitemid 40040381)
11. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. Cancer Cell 2003 4 6 437 450 10.1016/S1535-6108(03)00309-X 14706336 (Pubitemid 38050041)
12. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P, Anal Chem 2004 76 6 1560 1570 10.1021/ac0352171 15018552 (Pubitemid 38338398)
13. Differential exoprotease activities confer tumor-specific serum peptidome patterns. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, et al. J Clin Invest 2006 116 1 271 284 16395409 (Pubitemid 43121812)
14. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Sobin LH, Fleming ID, Cancer 1997 80 9 1803 1804 10.1002/(SICI)1097- 0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9 9351551
15. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, Nouretdinov I, Devetyarov D, Gentry-Maharaj A, Ford J, et al. Clin Chem 2010 56 2 262 271 10.1373/clinchem.2009.133363 20093557
16. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R, J Proteome Res 2005 4 3 972 981 10.1021/pr050046x 15952745 (Pubitemid 40863287)
17. A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R, Proteomics 2010 10 18 3388 3392 10.1002/pmic.201000100 20707003
18. Use of proteomic patterns in serum to identify ovarian cancer. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, et al. Lancet 2002 359 9306 572 577 10.1016/S0140- 6736(02)07746-2 11867112 (Pubitemid 34178440)
19. Mass spectrometry-based proteomics. Aebersold R, Mann M, Nature 2003 422 6928 198 207 10.1038/nature01511 12634793 (Pubitemid 36362757)
20. Clinical proteomics: written in blood. Liotta LA, Ferrari M, Petricoin E, Nature 2003 425 6961 905 10.1038/425905a 14586448 (Pubitemid 37376908)
21. Cancer proteomics: serum diagnostics for tumor marker discovery. Rai AJ, Chan DW, Ann N Y Acad Sci 2004 1022 286 294 10.1196/annals.1318.044 15251974 (Pubitemid 38951616)
22. Serum proteomics profiling-a young technology begins to mature. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA, Nat Biotechnol 2005 23 3 291 292 10.1038/nbt0305-291 15765078 (Pubitemid 41094414)
23. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. Diamandis EP, J Natl Cancer Inst 2004 96 5 353 356 10.1093/jnci/djh056 14996856 (Pubitemid 38351297)
24. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Baggerly KA, Morris JS, Coombes KR, Bioinformatics 2004 20 5 777 785 10.1093/bioinformatics/btg484 14751995 (Pubitemid 38443834)
25. Lessons from controversy: ovarian cancer screening and serum proteomics. Ransohoff DF, J Natl Cancer Inst 2005 97 4 315 319 10.1093/jnci/dji054 15713968 (Pubitemid 40310281)
26. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Diamandis EP, Mol Cell Proteomics 2004 3 4 367 378 10.1074/mcp.R400007-MCP200 14990683 (Pubitemid 38702090)
27. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Hortin GL, Clin Chem 2005 51 1 3 5 15613702 (Pubitemid 40024002)
28. Automated serum peptide profiling. Villanueva J, Lawlor K, Toledo-Crow R, Tempst P, Nat Protoc 2006 1 2 880 891 10.1038/nprot.2006.128 17406321
29. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P, Mol Cell Proteomics 2006 5 10 1840 1852 10.1074/mcp.M600229-MCP200 16896061 (Pubitemid 44688193)
30. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC, Am J Surg Pathol 2010 34 1 27 34 10.1097/PAS. 0b013e3181bc96f9 19898228
31. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C, et al. Clin Cancer Res 2009 15 11 3812 3819 10.1158/1078-0432.CCR-08- 2701 19470732
32. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Zabron AA, der Sluis VM H-v, Wadsworth CA, Laird F, Gierula M, Thillainayagam AV, Vlavianos P, Westaby D, Taylor-Robinson SD, Edwards RJ, et al. Am J Gastroenterol 2011 106 9 1711 1717 10.1038/ajg.2011.187 21670771
33. Role of aminopeptidases in the blood pressure regulation. Mitsui T, Nomura S, Itakura A, Mizutani S, Biol Pharm Bull 2004 27 6 768 771 10.1248/bpb.27.768 15187414 (Pubitemid 41701785)
34. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L, Thromb Haemost 1997 78 1 386 391 9198184 (Pubitemid 27289272)
35. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K, Clin Cancer Res 2002 8 12 3747 3754 12473585 (Pubitemid 35424765)
36. Tumor-specific gene delivery mediated by a novel peptide- polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13. Moffatt S, Wiehle S, Cristiano RJ, Hum Gene Ther 2005 16 1 57 67 10.1089/hum.2005.16.57 15703489 (Pubitemid 40250332)
37. Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C, Cancer Res 2003 63 23 8500 8506 14679016 (Pubitemid 37549507)
38. Ectopeptidases are differentially expressed in hepatocellular carcinomas. Rocken C, Carl-McGrath S, Grantzdorffer I, Mantke R, Roessner A, Lendeckel U, Int J Oncol 2004 24 3 487 495 14767532
39. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E, Cancer Res 2000 60 3 722 727 10676659 (Pubitemid 30094573)
40. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF, Lancet Oncol 2006 7 3 230 240 10.1016/S1470-2045(06)70584-8 16510332 (Pubitemid 43286453)
41. Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry. Bergen HR 3rd, Vasmatzis G, Cliby WA, Johnson KL, Oberg AL, Muddiman DC, Dis Markers 2003 19 4-5 239 249 15266667 (Pubitemid 38869703)
42. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Orvisky E, Drake SK, Martin BM, Abdel-Hamid M, Ressom HW, Varghese RS, An Y, Saha D, Hortin GL, Loffredo CA, et al. Proteomics 2006 6 9 2895 2902 10.1002/pmic.200500443 16586431
43. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, Sauer J, Albrecht W, Malfertheiner P, Rocken C, J Proteome Res 2006 5 9 2152 2158 10.1021/pr060011c 16944926 (Pubitemid 44330807)